You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameGinseng
Accession NumberDB01404
TypeSmall Molecule
GroupsApproved, Nutraceutical
Description

Ginseng is promoted as an adaptogen (a product that increases the body’s resistance to stress), one which can to a certain extent be supported with reference to its anticarcinogenic and antioxidant properties. Ginseng is also known to contain phytoestrogens.

Structure
Thumb
SynonymsNot Available
Prescription ProductsNot Available
Generic Prescription ProductsNot Available
Over the Counter ProductsNot Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
CategoriesNot Available
CAS number50647-08-0
WeightNot Available
Chemical FormulaNot Available
InChI KeyNot Available
InChINot Available
IUPAC NameNot Available
SMILESNot Available
Taxonomy
ClassificationNot classified
Pharmacology
IndicationNot Available
PharmacodynamicsNot Available
Mechanism of actionNot Available
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
Metabolism
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal AbsorptionNot AvailableNot Available
Blood Brain BarrierNot AvailableNot Available
Caco-2 permeableNot AvailableNot Available
P-glycoprotein substrateNot AvailableNot Available
P-glycoprotein inhibitor INot AvailableNot Available
P-glycoprotein inhibitor IINot AvailableNot Available
Renal organic cation transporterNot AvailableNot Available
CYP450 2C9 substrateNot AvailableNot Available
CYP450 2D6 substrateNot AvailableNot Available
CYP450 3A4 substrateNot AvailableNot Available
CYP450 1A2 substrateNot AvailableNot Available
CYP450 2C9 substrateNot AvailableNot Available
CYP450 2D6 substrateNot AvailableNot Available
CYP450 2C19 substrateNot AvailableNot Available
CYP450 3A4 substrateNot AvailableNot Available
CYP450 inhibitory promiscuityNot AvailableNot Available
Ames testNot AvailableNot Available
CarcinogenicityNot AvailableNot Available
BiodegradationNot AvailableNot Available
Rat acute toxicityNot AvailableNot applicable
hERG inhibition (predictor I)Not AvailableNot Available
hERG inhibition (predictor II)Not AvailableNot Available
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage formsNot Available
Prices
Unit descriptionCostUnit
V-r panax ginseng 300 mg capsule0.18USD capsule
Ra ginseng 100 mg softgel0.17USD softgel capsule
Eql ginseng 100 mg caplet0.15USD caplet
Eql ginseng 100 mg softgel0.15USD softgel capsule
Korean ginseng 1000 mg tablet0.14USD tablet
Siberian ginseng 250 mg capsule0.14USD capsule
CVS Pharmacy ginseng 200 mg softgel0.13USD softgel capsule
Korean ginseng 518 mg cap0.13USD capsule
Korean ginseng 350 mg capsule0.09USD capsule
Ginseng 8 gr capsule0.08USD capsule
Siberian root 1000 mg capsule0.08USD capsule
Ginseng 250 mg capsule0.07USD capsule
Ra siberian ginseng 410 mg0.05USD each
Gnp ginseng root 410 mg capsule0.04USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted PropertiesNot Available
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Iwao Hachiya, Keizo Mochizuki, Yukio Kuwada, “Method of preparing dried ginseng for drug.” U.S. Patent US4446130, issued January, 1970.

US4446130
General Reference
  1. Lee YJ, Jin YR, Lim WC, Park WK, Cho JY, Jang S, Lee SK: Ginsenoside-Rb1 acts as a weak phytoestrogen in MCF-7 human breast cancer cells. Arch Pharm Res. 2003 Jan;26(1):58-63. Pubmed
  2. Chan RY, Chen WF, Dong A, Guo D, Wong MS: Estrogen-like activity of ginsenoside Rg1 derived from Panax notoginseng. J Clin Endocrinol Metab. 2002 Aug;87(8):3691-5. Pubmed
  3. Lee Y, Jin Y, Lim W, Ji S, Choi S, Jang S, Lee S: A ginsenoside-Rh1, a component of ginseng saponin, activates estrogen receptor in human breast carcinoma MCF-7 cells. J Steroid Biochem Mol Biol. 2003 Mar;84(4):463-8. Pubmed
  4. McElhaney JE, Gravenstein S, Cole SK, Davidson E, O’neill D, Petitjean S, Rumble B, Shan JJ: A placebo-controlled trial of a proprietary extract of North American ginseng (CVT-E002) to prevent acute respiratory illness in institutionalized older adults. J Am Geriatr Soc. 2004 Jan;52(1):13-9. Pubmed
  5. Lewis WH, Zenger VE, Lynch RG: No adaptogen response of mice to ginseng and Eleutherococcus infusions. J Ethnopharmacol. 1983 Aug;8(2):209-14. Pubmed
External Links
ATC CodesNot Available
AHFS Codes
  • 92:01.00*
  • 92:02.00*
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (73.2 KB)
Interactions
Drug Interactions
Drug
BumetanideGinseng may decrease the therapeutic effect of diuretic, bumetanide.
DigoxinChanges in digoxin serum levels
Ethacrynic acidGinseng may decrease the therapeutic effect of diuretic, ethacrynic acid.
FurosemideGinseng decreases the therapeutic effect
Ginkgo bilobaAdditive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.
KetoprofenIncreased risk of bleeding due to additive anticoagulant properties of the two agents. Concomitant therapy should be avoided or monitored carefully for bleeding, bruising and altered mental status, which may be caused by CNS bleeds.
NifedipineGinseng increases the effect and toxicity of nifedipine
SulindacGinseng may enhance the anticoagulant effect of sulindac. Increased risk of bleeding, bruising and altered mental status due to CNS bleeds. Concomitant therapy should be avoided.
TenecteplaseIncreased risk of bleeding.
Tiaprofenic acidIncreased risk of bleeding due to additive antiplatelet properties of the two agents. Concomitant therapy should be avoided or monitored carefully for bleeding, bruising and altered mental status, which may be caused by CNS bleeds.
TolmetinIncreased risk of bleeding due to additive antiplatelet properties of the two agents. Concomitant therapy should be avoided or monitored carefully for bleeding, bruising and altered mental status, which may be caused by CNS bleeds.
TrandolaprilGinseng may antagonize the antihypertensive effect of Trandolapril. Monitor Trandolapril efficacy.
UrokinaseIncreased risk of bleeding.
WarfarinAdditive anticoagulant effects increase the risk of bleeding. Concomitant therapy should be avoided.
Food InteractionsNot Available

Targets

1. Interleukin-6

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: antagonist

Components

Name UniProt ID Details
Interleukin-6 P05231 Details

References:

  1. Kim DH, Moon YS, Lee TH, Jung JS, Suh HW, Song DK: The inhibitory effect of ginseng saponins on the stress-induced plasma interleukin-6 level in mice. Neurosci Lett. 2003 Dec 15;353(1):13-6. Pubmed
  2. Kim SJ, Jeong HJ, Yi BJ, Kang TH, An NH, Lee EH, Yang DC, Kim HM, Hong SH, Um JY: Transgenic Panax ginseng inhibits the production of TNF-alpha, IL-6, and IL-8 as well as COX-2 expression in human mast cells. Am J Chin Med. 2007;35(2):329-39. Pubmed

2. Prostaglandin G/H synthase 2

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Prostaglandin G/H synthase 2 P35354 Details

References:

  1. Yim HW, Jong HS, Kim TY, Choi HH, Kim SG, Song SH, Kim J, Ko SG, Lee JW, Kim TY, Bang YJ: Cyclooxygenase-2 inhibits novel ginseng metabolite-mediated apoptosis. Cancer Res. 2005 Mar 1;65(5):1952-60. Pubmed
  2. Seo JY, Lee JH, Kim NW, Her E, Chang SH, Ko NY, Yoo YH, Kim JW, Seo DW, Han JW, Kim YM, Choi WS: Effect of a fermented ginseng extract, BST204, on the expression of cyclooxygenase-2 in murine macrophages. Int Immunopharmacol. 2005 May;5(5):929-36. Pubmed
  3. Kim SJ, Jeong HJ, Yi BJ, Kang TH, An NH, Lee EH, Yang DC, Kim HM, Hong SH, Um JY: Transgenic Panax ginseng inhibits the production of TNF-alpha, IL-6, and IL-8 as well as COX-2 expression in human mast cells. Am J Chin Med. 2007;35(2):329-39. Pubmed

3. Aryl hydrocarbon receptor

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: agonist

Components

Name UniProt ID Details
Aryl hydrocarbon receptor P35869 Details

References:

  1. Wang Y, Ye X, Ma Z, Liang Q, Lu B, Tan H, Xiao C, Zhang B, Gao Y: Induction of cytochrome P450 1A1 expression by ginsenoside Rg1 and Rb1 in HepG2 cells. Eur J Pharmacol. 2008 Dec 28;601(1-3):73-8. Epub 2008 Nov 11. Pubmed

Comments
comments powered by Disqus
Drug created on July 13, 2007 14:21 / Updated on September 13, 2013 11:06